search
Back to results

Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?

Primary Purpose

Larynx Disease, Gastroesophageal Reflux

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Prevacid
Esophageal and Laryngeal Biopsies
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Larynx Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

GERD

  • Documented erosive esophagitis:

    • Patients will be newly diagnosed with esophageal erosion at initial visit via EGD
    • Patients with non-erosive esophagitis who have been responsive to PPI

LPR

  • Diagnosed via Head & Neck Institute endoscopists:

    • pts with chronic (> 3-months) history of hoarseness, throat clearing, sore- or burning throat and globus
    • Documentation of LPR using Larynx/Pharynx exam.

This group is commonly evaluated at the Vanderbilt Voice Center.

Exclusion Criteria:

  • Age < 18yrs
  • Pregnancy
  • Patients with contra-indications for EGD
  • Patients on corticosteroids
  • Active smokers
  • Patients with a history of regular (> 2 /day) alcohol use.
  • Use of antacid (PPI, H2RB) within last 30 days
  • Use of any/all medications affecting gastrointestinal motility
  • Known history of: Barrett's esophagus, Peptic stricture, Pyloric stenosis, Gastric resection
  • Patients unable to give informed consent
  • Patients unable to comply with follow-up
  • Patients with known contraindication to lansoprazole.
  • Contraindications to biopsy: Taking anticoagulants other than aspirin (Coumadin, Plavix) or allergic to the local anesthetics.

Sites / Locations

  • Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients with documented GERD or laryngopharyngeal reflux

Arm Description

Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.

Outcomes

Primary Outcome Measures

Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy
Dilation of inter cellular spaces (the space within the cell) is reported to be an early morphological (structure and form) marker in gastro-oesophageal reflux. Using electron microscopy, the distance between epithelial cells is quantified.

Secondary Outcome Measures

Full Information

First Posted
March 5, 2007
Last Updated
February 21, 2017
Sponsor
Vanderbilt University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00444145
Brief Title
Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?
Official Title
Do Laryngeal Biopsy Findings Predict Treatment Response in Suspected Laryngopharyngeal Reflux
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
March 2007 (Actual)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to determine if tissue changes are predictor of clinical response to therapy. The hypothesis is that the patients who have laryngeal signs and symptoms related to acid reflux, will have ultrastructural changes on a laryngeal biopsy which are predictors of response to therapy.
Detailed Description
Gastroesophageal reflux disease (GERD) has been implicated, in part, as the cause of various laryngeal signs and symptoms (1-7). This is often termed reflux laryngitis, ear, nose, and throat (ENT) reflux, or laryngopharyngeal reflux (LPR). GERD was first described to be a causative agent in developing contact ulcers of the larynx (8), and since this early report other routinely observed laryngeal signs are now attributed to LPR. These include laryngeal edema/erythema, vocal cord granulomas and polyps, posterior cricoid cobblestoning, interarytenoid changes, and subglottic stenosis. In addition, patient symptoms attributed to LPR include hoarseness, sore or burning throat, chronic cough, throat clearing, globus, nocturnal laryngospasm, otalgia, post-nasal drip, and dysphagia. GERD occurs in 7% - 25% of the population on a daily or monthly basis, respectively (9). It is estimated that up to 10% of patients presenting to ENT physicians do so because of complaints that are thought to be related to LPR (2). The current management of patients with suspected LPR complaints include either 1. empiric therapy using proton pump inhibitors (PPI's) or 2. Ambulatory 24-hour pH monitoring to test for GERD before beginning treatment. Because of the uncertainty and subjectivity of the ENT laryngeal examination in diagnosing LPR, both algorithms fall short of ideal in treating these patients. In a recent review of the literature, remarkably, up to 50% of patients with laryngoscopic signs suggesting LPR do not respond to aggressive acid suppression and do not have abnormal esophageal acid reflux values on pH testing (10). Yet, in this subset of patients LPR continues to be implicated as the probable etiology of the patient's laryngeal signs and symptoms. Calabrese, et al. recently looked at the reversibility of GERD related ultrastructural alterations in the esophagus using a PPI. Lower esophageal biopsies were analyzed with electron microscopy (EM) for ultrastructural alterations attributed to GERD; that is, dilation of intracellular spaces. Patients were then treated with a PPI and re-biopsied for analysis of any changes of healing that may have occurred in these ultrastructural alterations. Not surprisingly, the ultrastructural alterations showed complete recovery (reduction of dilated intracellular spaces) after treatment with a PPI. Additionally resolution of patient's symptoms coincided with recovery of ultrastructural alterations (11). No such biopsies looking for LPR related changes in the larynx have ever been performed in human subjects. Our initial study which is also submitted for review will provide data on the prevalence of biopsy findings in controls, GERD and LPR patients. Subsequent to this prevalence study, the importance of these findings will be assessed based to determine if these findings will predict response to acid suppressive therapy. In sum, LPR is an extremely subjective diagnosis, in which nearly half of all patients do not have an abnormal 24hr pH study, nor do they respond to the standard GERD therapy of acid suppression. Finding an alternative objective criterion for GERD induced laryngitis would be an important clinical discovery. To date, there are no data on microscopic changes in the larynx of patients suspected of having LPR. The most important question which this protocol will address is if laryngeal findings specifically by either routine microscopy or electron microscopy would predict response to PPI therapy. This would then result in being able to identify GERD related laryngitis from non-GERD related causes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Larynx Disease, Gastroesophageal Reflux

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
38 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patients with documented GERD or laryngopharyngeal reflux
Arm Type
Experimental
Arm Description
Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
Intervention Type
Drug
Intervention Name(s)
Prevacid
Other Intervention Name(s)
lansoprazole
Intervention Description
30 mg bid for 3 months
Intervention Type
Procedure
Intervention Name(s)
Esophageal and Laryngeal Biopsies
Other Intervention Name(s)
esophagogastroduodenoscopy
Intervention Description
repeat egd with biopsy after Prevacid 30 mg bid for 3 months
Primary Outcome Measure Information:
Title
Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy
Description
Dilation of inter cellular spaces (the space within the cell) is reported to be an early morphological (structure and form) marker in gastro-oesophageal reflux. Using electron microscopy, the distance between epithelial cells is quantified.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: GERD Documented erosive esophagitis: Patients will be newly diagnosed with esophageal erosion at initial visit via EGD Patients with non-erosive esophagitis who have been responsive to PPI LPR Diagnosed via Head & Neck Institute endoscopists: pts with chronic (> 3-months) history of hoarseness, throat clearing, sore- or burning throat and globus Documentation of LPR using Larynx/Pharynx exam. This group is commonly evaluated at the Vanderbilt Voice Center. Exclusion Criteria: Age < 18yrs Pregnancy Patients with contra-indications for EGD Patients on corticosteroids Active smokers Patients with a history of regular (> 2 /day) alcohol use. Use of antacid (PPI, H2RB) within last 30 days Use of any/all medications affecting gastrointestinal motility Known history of: Barrett's esophagus, Peptic stricture, Pyloric stenosis, Gastric resection Patients unable to give informed consent Patients unable to comply with follow-up Patients with known contraindication to lansoprazole. Contraindications to biopsy: Taking anticoagulants other than aspirin (Coumadin, Plavix) or allergic to the local anesthetics.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael F Vaezi, MD,PhD
Organizational Affiliation
Vanderbilt University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232-5280
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?

We'll reach out to this number within 24 hrs